These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 26914813)

  • 1. A Multiplex Protein Panel Applied to Cerebrospinal Fluid Reveals Three New Biomarker Candidates in ALS but None in Neuropathic Pain Patients.
    Lind AL; Wu D; Freyhult E; Bodolea C; Ekegren T; Larsson A; Gustafsson MG; Katila L; Bergquist J; Gordh T; Landegren U; Kamali-Moghaddam M
    PLoS One; 2016; 11(2):e0149821. PubMed ID: 26914813
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Label-Free LC-MS/MS Proteomic Analysis of Cerebrospinal Fluid Identifies Protein/Pathway Alterations and Candidate Biomarkers for Amyotrophic Lateral Sclerosis.
    Collins MA; An J; Hood BL; Conrads TP; Bowser RP
    J Proteome Res; 2015 Nov; 14(11):4486-501. PubMed ID: 26401960
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduced levels of alpha-1-antitrypsin in cerebrospinal fluid of amyotrophic lateral sclerosis patients: a novel approach for a potential treatment.
    Wormser U; Mandrioli J; Vinceti M; Fini N; Sintov A; Brodsky B; Proskura E; Finkelstein Y
    J Neuroinflammation; 2016 Jun; 13(1):131. PubMed ID: 27245439
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is cerebrospinal fluid obtained for diagnostic purpose a good material for biomarker studies in amyotrophic lateral sclerosis?
    Chełstowska B; Kuźma-Kozakiewicz M
    Biomarkers; 2014 Nov; 19(7):571-7. PubMed ID: 25133306
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Spinal Cord Stimulation Alters Protein Levels in the Cerebrospinal Fluid of Neuropathic Pain Patients: A Proteomic Mass Spectrometric Analysis.
    Lind AL; Emami Khoonsari P; Sjödin M; Katila L; Wetterhall M; Gordh T; Kultima K
    Neuromodulation; 2016 Aug; 19(6):549-62. PubMed ID: 27513633
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biomarker-based predictive models for prognosis in amyotrophic lateral sclerosis.
    Su XW; Simmons Z; Mitchell RM; Kong L; Stephens HE; Connor JR
    JAMA Neurol; 2013 Dec; 70(12):1505-11. PubMed ID: 24145899
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Do fragments and glycosylated isoforms of alpha-1-antitrypsin in CSF mirror spinal pathophysiological mechanisms in chronic peripheral neuropathic pain? An exploratory, discovery phase study.
    Bäckryd E; Edström S; Gerdle B; Ghafouri B
    BMC Neurol; 2018 Aug; 18(1):116. PubMed ID: 30115020
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased cerebrospinal fluid levels of substance P in patients with amyotrophic lateral sclerosis. Short communication.
    Matsuishi T; Nagamitsu S; Shoji H; Itoh M; Takashima S; Iwaki T; Shida N; Yamashita Y; Sakai T; Kato H
    J Neural Transm (Vienna); 1999; 106(9-10):943-8. PubMed ID: 10599876
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A CSF biomarker panel for identification of patients with amyotrophic lateral sclerosis.
    Mitchell RM; Freeman WM; Randazzo WT; Stephens HE; Beard JL; Simmons Z; Connor JR
    Neurology; 2009 Jan; 72(1):14-9. PubMed ID: 18987350
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cerebrospinal fluid levels of chromogranin A and phosphorylated neurofilament heavy chain are elevated in amyotrophic lateral sclerosis.
    Kaiserova M; Grambalova Z; Otruba P; Stejskal D; Prikrylova Vranova H; Mares J; Mensikova K; Kanovsky P
    Acta Neurol Scand; 2017 Oct; 136(4):360-364. PubMed ID: 28185258
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proteomic studies in the discovery of cerebrospinal fluid biomarkers for amyotrophic lateral sclerosis.
    Barschke P; Oeckl P; Steinacker P; Ludolph A; Otto M
    Expert Rev Proteomics; 2017 Sep; 14(9):769-777. PubMed ID: 28799854
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Measurement of cystatin C levels in the cerebrospinal fluid of patients with amyotrophic lateral sclerosis.
    Ren Y; Zhu W; Cui F; Yang F; Chen Z; Ling L; Huang X
    Int J Clin Exp Pathol; 2015; 8(5):5419-26. PubMed ID: 26191245
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of potential CSF biomarkers in ALS.
    Pasinetti GM; Ungar LH; Lange DJ; Yemul S; Deng H; Yuan X; Brown RH; Cudkowicz ME; Newhall K; Peskind E; Marcus S; Ho L
    Neurology; 2006 Apr; 66(8):1218-22. PubMed ID: 16481598
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monitoring CSF proteome alterations in amyotrophic lateral sclerosis: obstacles and perspectives in translating a novel marker panel to the clinic.
    von Neuhoff N; Oumeraci T; Wolf T; Kollewe K; Bewerunge P; Neumann B; Brors B; Bufler J; Wurster U; Schlegelberger B; Dengler R; Zapatka M; Petri S
    PLoS One; 2012; 7(9):e44401. PubMed ID: 22970211
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exploring Cerebrospinal Fluid IgG N-Glycosylation as Potential Biomarker for Amyotrophic Lateral Sclerosis.
    Costa J; Streich L; Pinto S; Pronto-Laborinho A; Nimtz M; Conradt HS; de Carvalho M
    Mol Neurobiol; 2019 Aug; 56(8):5729-5739. PubMed ID: 30674035
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Total tau is increased, but phosphorylated tau not decreased, in cerebrospinal fluid in amyotrophic lateral sclerosis.
    Wilke C; Deuschle C; Rattay TW; Maetzler W; Synofzik M
    Neurobiol Aging; 2015 Feb; 36(2):1072-4. PubMed ID: 25453560
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antioxidant capacity and protein oxidation in cerebrospinal fluid of amyotrophic lateral sclerosis.
    Siciliano G; Piazza S; Carlesi C; Del Corona A; Franzini M; Pompella A; Malvaldi G; Mancuso M; Paolicchi A; Murri L
    J Neurol; 2007 May; 254(5):575-80. PubMed ID: 17426914
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proteomic profiling of cerebrospinal fluid identifies biomarkers for amyotrophic lateral sclerosis.
    Ranganathan S; Williams E; Ganchev P; Gopalakrishnan V; Lacomis D; Urbinelli L; Newhall K; Cudkowicz ME; Brown RH; Bowser R
    J Neurochem; 2005 Dec; 95(5):1461-71. PubMed ID: 16313519
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduced angiotensin II levels in the cerebrospinal fluid of patients with amyotrophic lateral sclerosis.
    Kawajiri M; Mogi M; Higaki N; Tateishi T; Ohyagi Y; Horiuchi M; Miki T; Kira JI
    Acta Neurol Scand; 2009 May; 119(5):341-4. PubMed ID: 18798831
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elevated cerebrospinal fluid neurofilament light levels in patients with amyotrophic lateral sclerosis: a possible marker of disease severity and progression.
    Tortelli R; Ruggieri M; Cortese R; D'Errico E; Capozzo R; Leo A; Mastrapasqua M; Zoccolella S; Leante R; Livrea P; Logroscino G; Simone IL
    Eur J Neurol; 2012 Dec; 19(12):1561-7. PubMed ID: 22680408
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.